It has been speculated that C3aR or C5aR antagonists may be useful in cancer immunotherapy as adjuvants to vaccine-based approaches in patients with adverse prognoses, with the benefit of lower treatment toxicity than conventional cytotoxic chemotherapy 1. The gene discussed is C5AR1; the disease is cancer.